Allogene Therapeutics, Inc. (ALLO) Deep Dive Video
Summary
Allogene’s 2026 inflection point could determine whether off-the-shelf CAR T becomes a scalable, outpatient, frontline and autoimmune treatment platform—or remains an unproven biotech promise.